Monday, May 16, 2005

OncoLink coverage of the Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2005, in Orlando, FL. OncoLink reporters provide in-depth, up-to-the-minute coverage of sessions and presentations.

A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of the NSABP Protocol C-07. Presenter: N. WolmarkPresenter's Affiliation: Allegheny General Hospital, Pittsburgh, PennsylvaniaType of Session: ScientificBackground Oxaliplatin is a new chemotherapeutic agent with demonstrated activity in colorectal cancer. A previously...
A Prospective Randomized Study of Adjuvant Chemotherapy with Navelbine + Cisplatin in Completely Resected Non-Small Cell Lung (the ANITA trial) Presenter: J.Y. DouillardPresenter's Affiliation: Adjuvant Navelbine International Trialist AssociationType of Session: ScientificBackground Recent randomized trials have shown an overall survival (OS) benefit to adjuvant chemotherapy added to...
A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL Presenter: M.A. WeissPresenter's Affiliation: Memorial Sloan-Kettering Cancer CenterType of Session: ScientificBackground Induction therapy for adult ALL is similar across most regimens The most commonly used regimens employ vincristine, a...
A Randomized Trial of Radical Surgery versus Thoracic Radiotherapy After Response to Induction Chemotherapy in Patients with Histo-/Cytologically Proven Irresectable Stage IIIA-N2 NSCLC (EORTC 09841) Presenter: J. van MeerbeeckPresenter's Affiliation: EORTC Lung Cancer GroupType of Session: ScientificBackground Stage IIIA non-small cell lung cancer (NSCLC) with stage N2 disease is a heterogeneous group of patients representing 15% of all cases...
Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Intervention Nutrition Study (WINS) Presenter: R.T. ChlebowskiPresenter's Affiliation: The WINS InvestigatorsType of Session: PlenaryBackground Laboratory and retrospective research has suggested that dietary fat intake may be related to outcomes in breast cancer patients. The...
JGOG2033: randomized phase III trial of whole pelvic radiotherapy vs cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma Presenter: S. SagaePresenter's Affiliation: Sapporo Medical UniversityType of Session: ScientificBackground Optimal adjuvant therapy for endometrial carcinoma has not been clearly defined. Radiation therapy is generally used for earlier...
Low dose involved field radiation (IFRT) or no further treatment following complete response to initial chemotherapy in young adult (YA) patients 16-21years of age with Hodgkin's disease (HD): The Children's Cancer Group (CCG) experience Presenter: J. NachmanPresenter's Affiliation: Children's Hospital, Redmond, WAType of Session: ScientificBackground Little data exist regarding treatment outcomes in HD patients aged 16-21 years. The optimal combination of chemotherapy with...
Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Presenter: A. deGramontPresenter's Affiliation: Hopital Saint Antoine, Paris, FranceType of Session: ScientificBackground Oxaliplatin is a new chemotherapeutic agent with demonstrated activity in colorectal cancer. This abstract presents an update...
Phase III study of concurrent chemortherapy and radiotherapy (CT/RT) vs. CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) Presenter: Kathy AlbainPresenter's Affiliation: RTOGType of Session: ScientificBackground Patients with stage IIIA NSCLC and N2 (mediastinal) disease have a poor outcome, with long term overall survival consistently reported to be approximately 20%...
Preoperative (preop) radiotherapy (RT) +/- 5FU/folinic acid (FA) in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. Presenter: J.P. GerardPresenter's Affiliation: Center Antoine Lacassagne, Nice, FranceType of Session: ScientificBackground Multiple studies have demonstrated the safety and efficacy of preoperative radiation therapy for the treatment of advanced...
Prevalence and severity of chronic diseases in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study Presenter: K.C. OeffingerPresenter's Affiliation: University of Texas Southwestern Medical CenterType of Session: PlenaryBackground The cure rate of childhood cancers is now >78% Currently, 1 out of every 640 people age 18-45 are...
Randomized Phase III Trial Comparing Infused Irinotecan/5-flurouracil (5-FU)/Folinic Acid (IF) versus 5-FU/FA (F) in Stage III Colon Cancer Patients (PETACC-3, v307) Presenter: E. Van CutsemPresenter's Affiliation: PETACC-3 investigatorsType of Session: ScientificBackground Use of post-operative chemotherapy in patients with stage III colon cancer is well established. Irinotecan and infusional 5-FU and FA are...
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results Presenter: K. PistersPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground Five year Overall Survival (OS) for stages T2NO-T3N1 NSCLC are low, ranging from 9-38%. When this study was designed in the late 1990s,...
Symptom Response in NSCLC Patients Treated with Erlotinib: QOL Analysis of the NCIC CTG BR.21 Trial Presenter: A. BezjakPresenter's Affiliation: National Cancer Institute CanadaType of Session: ScientificBackground The NCIC CTG BR.21 trial was a randomized phase III trial of Erlotinib (Tarceva) and placebo as second-line therapy for patients...
The David A. Karnofsky Memorial Award and Lecture Since 1970, ASCO has been awarding outstanding individuals who have contributed to the both to the field of oncology and to the way oncologists think about this discipline, with a David A. Karnofsky award. This award is named after one of the true...
The Science of Oncology Award ASCO 2005 This year at ASCO, a new award was created in an attempt to recognize the important contribution that basic and translational scientists make to the field of oncology. The Science of Oncology Award attempts to highlight the importance of basic and...